{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T16:50:44Z","timestamp":1761929444907},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Vet Res"],"published-print":{"date-parts":[[2010,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The reduced drug accumulation based on enhanced drug efflux and metabolic capacity, identified in triclabendazole (TCBZ)-resistant <jats:italic>Fasciola hepatica<\/jats:italic> may contribute to the development of resistance to TCBZ. The aim of this work was to evaluate the pharmacokinetics and clinical efficacy of TCBZ administered alone or co-administered with ivermectin (IVM, efflux modulator) and methimazole (MTZ, metabolic inhibitor) in TCBZ-resistant <jats:italic>F. hepatica<\/jats:italic>-parasitized sheep. Sheep infected with TCBZ-resistant <jats:italic>F. hepatica<\/jats:italic> (Sligo isolate) were divided into three groups (n = 4): untreated control, TCBZ-treated (i.r. at 10 mg\/kg) and TCBZ+IVM+MTZ treated sheep (10 i.r., 0.2 s.c. and 1.5 i.m. mg\/kg, respectively). Plasma samples were collected and analysed by HPLC. In the clinical efficacy study, the animals were sacrificed at 15 days post-treatment to evaluate the comparative efficacy against TCBZ-resistant <jats:italic>F. hepatica<\/jats:italic>.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The presence of IVM and MTZ did not affect the plasma disposition kinetics of TCBZ metabolites after the i.r. administration of TCBZ. The AUC value of TCBZ.SO obtained after TCBZ administration (653.9 \u00b1 140.6 \u03bcg.h\/ml) was similar to that obtained after TCBZ co-administered with IVM and MTZ (650.7 \u00b1 122.8 \u03bcg.h\/ml). Efficacy values of 56 and 38% were observed for TCBZ alone and for the combined treatment, respectively. No statistical differences (P &gt; 0.05) were observed in fluke counts between treated groups and untreated control, which confirm the resistant status of the Sligo isolate.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The presence of IVM and MTZ did not affect the disposition kinetics of TCBZ and its metabolites. Thus, the combined drug treatment did not reverse the poor efficacy of TCBZ against TCBZ-resistant <jats:italic>F. hepatica<\/jats:italic>.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1746-6148-6-8","type":"journal-article","created":{"date-parts":[[2010,2,3]],"date-time":"2010-02-03T19:15:12Z","timestamp":1265224512000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Unchanged triclabendazole kinetics after co-administration with ivermectin and methimazole: failure of its therapeutic activity against triclabendazole-resistant liver flukes"],"prefix":"10.1186","volume":"6","author":[{"given":"Laura","family":"Ceballos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Fairweather","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Lanusse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,2,3]]},"reference":[{"key":"188_CR1","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1136\/vr.113.14.315","volume":"113","author":"J Boray","year":"1983","unstructured":"Boray J, Crowfoot P, Strong M, Allison J, Schellenbaum M, von Orelli M, Sarasin G: Treatment of immature and mature Fasciola hepatica infections in sheep with triclabendazole. Vet Rec. 1983, 113: 315-317.","journal-title":"Vet Rec"},{"key":"188_CR2","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1079\/JOH2005298","volume":"79","author":"I Fairweather","year":"2005","unstructured":"Fairweather I: Triclabendazole: new skills to unravel an old(ish) enigma. J Helmintol. 2005, 79: 227-234. 10.1079\/JOH2005298.","journal-title":"J Helmintol"},{"key":"188_CR3","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1017\/S0022149X09321173","volume":"83","author":"I Fairweather","year":"2009","unstructured":"Fairweather I: Triclabendazole progress report, 2005-2009: an advancement of learning?. J Helminthol. 2009, 83: 139-150. 10.1017\/S0022149X09321173.","journal-title":"J Helminthol"},{"key":"188_CR4","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1046\/j.1365-3156.2001.00777.x","volume":"6","author":"M Ouellette","year":"2001","unstructured":"Ouellette M: Biochemical and molecular mechanism of drug resistance in parasites. Trop Med Int Health. 2001, 6: 874-882. 10.1046\/j.1365-3156.2001.00777.x.","journal-title":"Trop Med Int Health"},{"key":"188_CR5","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s00436-003-1003-6","volume":"92","author":"M Robinson","year":"2004","unstructured":"Robinson M, Lawson J, Trudgett A, Hoey E, Fairweather I: The comparative metabolism of triclabendazole sulphoxide by triclabendazole-susceptible and triclabendazole-resistant Fasciola hepatica. Parasitol Res. 2004, 92: 205-210. 10.1007\/s00436-003-1003-6.","journal-title":"Parasitol Res"},{"key":"188_CR6","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1017\/S0031182005007997","volume":"131","author":"L Alvarez","year":"2005","unstructured":"Alvarez L, Solana H, Mottier L, Virkel G, Fairweather I, Lanusse C: Altered drug influx\/efflux and enhanced metabolic activity in triclabendazole-resistant liver flukes. Parasitology. 2005, 131: 501-510. 10.1017\/S0031182005007997.","journal-title":"Parasitology"},{"key":"188_CR7","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1645\/GE-922R.1","volume":"92","author":"L Mottier","year":"2006","unstructured":"Mottier L, Alvarez L, Fairweather I, Lanusse C: Resistance-induced changes in triclabendazole transport in Fasciola hepatica : Ivermectin reversal effect. J Parasitol. 2006, 92: 1355-1360. 10.1645\/GE-922R.1.","journal-title":"J Parasitol"},{"key":"188_CR8","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/j.1365-2885.2006.00762_4.x","volume":"29","author":"J Dupuy","year":"2006","unstructured":"Dupuy J, Lespine A, Alvinerie M: Influence of anthelmintic drugs on P-glycoprotein transport activity in mdr-1-LLC-PK1 cells. J Vet Pharmacol Therap. 2006, 29: 115-119. 10.1111\/j.1365-2885.2006.00762_4.x.","journal-title":"J Vet Pharmacol Therap"},{"key":"188_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S0006-2952(96)00656-9","volume":"53","author":"J Pouliot","year":"1997","unstructured":"Pouliot J, Lheureux F, Liu Z, Prichard R, Georges E: Reversal of P-glycoprotein-associated multidrug resistance by ivermectin. Biochem Pharmacol. 1997, 53: 17-25. 10.1016\/S0006-2952(96)00656-9.","journal-title":"Biochem Pharmacol"},{"key":"188_CR10","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/S0166-6851(97)00215-6","volume":"91","author":"M Xu","year":"1998","unstructured":"Xu M, Molento M, Blackhall W, Ribeiro P, Beech P, Prichard R: Ivermectin resistance in nematodes may be caused by alteration of P-glycoprotein homolog. Mol Biochem Parasitol. 1998, 91: 327-335. 10.1016\/S0166-6851(97)00215-6.","journal-title":"Mol Biochem Parasitol"},{"key":"188_CR11","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/S0924-8579(03)00221-8","volume":"22","author":"D Kerboeuf","year":"2003","unstructured":"Kerboeuf D, Blackhall W, Kaminsky R, Von Samson-Himmelstjerna G: P-glycoprotein in helminths: Function and perspectives for anthelmintic treatment and reversal of resistance. Int J Antimicrob Agents. 2003, 22: 332-346. 10.1016\/S0924-8579(03)00221-8.","journal-title":"Int J Antimicrob Agents"},{"key":"188_CR12","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.pt.2004.07.010","volume":"20","author":"A Wolstenholme","year":"2004","unstructured":"Wolstenholme A, Fairweather I, Prichard R, Von Samson-Himmelstjerna G, Sangster N: Drug resistance in veterinary parasites. Trends in Parasitol. 2004, 20: 469-476. 10.1016\/j.pt.2004.07.010.","journal-title":"Trends in Parasitol"},{"key":"188_CR13","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1097\/00001813-199609000-00005","volume":"7","author":"A Didier","year":"1996","unstructured":"Didier A, Loor F: The abamectin derivative ivermectin is a potent P-glycoprotein inhibitor. Anticancer Drugs. 1996, 7: 745-751.","journal-title":"Anticancer Drugs"},{"key":"188_CR14","doi-asserted-by":"crossref","unstructured":"Halferty L, Brennan GP, Trudgett A, Hoey L, Fairweather I: Relative activity of triclabendazole metabolites against the liver fluke, Fasciola hepatica. Veterinary Parasitology. 159: 126-138. 10.1016\/j.vetpar.2008.10.007.","DOI":"10.1016\/j.vetpar.2008.10.007"},{"key":"188_CR15","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1017\/S0031182008005222","volume":"136","author":"C Devine","year":"2009","unstructured":"Devine C, Brennan GP, Lanusse C, Alvarez L, Trudgett A, Hoey E, Fairweather I: Effect of the metabolic inhibitor, methimazole on the drug susceptibility of a triclabendazole-resistant isolate of Fasciola hepatica. Parasitology. 2009, 136: 183-192. 10.1017\/S0031182008005222.","journal-title":"Parasitology"},{"key":"188_CR16","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/j.1365-2885.2008.00953.x","volume":"31","author":"L Alvarez","year":"2008","unstructured":"Alvarez L, Lifschitz A, Entrocasso C, Manazza J, Mottier L, Borda B, Virkel G, Lanusse C: Evaluation of the interaction between ivermectin and albendazole following their combined use in lambs. J Vet Pharmacol Therap. 2008, 31: 230-239. 10.1111\/j.1365-2885.2008.00953.x.","journal-title":"J Vet Pharmacol Therap"},{"key":"188_CR17","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.tvjl.2008.06.001","volume":"182","author":"A Lifschitz","year":"2009","unstructured":"Lifschitz A, Virkel G, Ballent M, Sallovitz J, Lanusse C: Combined use of ivermectin and triclabendazole in sheep: in vitro and in vivo characterisation of their pharmacological interaction. Vet J. 2009, 182: 261-268. 10.1016\/j.tvjl.2008.06.001.","journal-title":"Vet J"},{"key":"188_CR18","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/j.1365-2885.2006.00735.x","volume":"29","author":"G Virkel","year":"2006","unstructured":"Virkel G, Lifschitz A, Sallovitz J, Pis A, Lanusse C: Assessment of the main metabolism pathways for the flukicidal compound triclabendazole in sheep. J Vet Pharmacol Therap. 2006, 29: 213-223. 10.1111\/j.1365-2885.2006.00735.x.","journal-title":"J Vet Pharmacol Therap"},{"key":"188_CR19","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/j.1365-2885.2008.01006.x","volume":"32","author":"G Virkel","year":"2009","unstructured":"Virkel G, Lifschitz A, Sallovitz J, Ballent M, Scarcella S, Lanusse C: Inhibition of cytochrome P450 activity enhances the systemic availability of triclabendazole metabolites in sheep. J Vet Pharmacol Therap. 2009, 32: 79-86. 10.1111\/j.1365-2885.2008.01006.x.","journal-title":"J Vet Pharmacol Therap"},{"key":"188_CR20","volume-title":"Manual of Veterinary Parasitological Laboratory Techniques","author":"Ministry of Agriculture Fisheries and Food (M.A.F.F.)","year":"1987","unstructured":"Ministry of Agriculture Fisheries and Food (M.A.F.F.): Manual of Veterinary Parasitological Laboratory Techniques. London, England 1987."},{"key":"188_CR21","doi-asserted-by":"publisher","first-page":"669","DOI":"10.2460\/javma.2001.218.669","volume":"218","author":"AVMA","year":"2001","unstructured":"AVMA: Report of the AVMA panel on euthanasia. J Am Vet Med Assoc. 2001, 218: 669-696. 10.2460\/javma.2001.218.669.","journal-title":"J Am Vet Med Assoc"},{"key":"188_CR22","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1136\/vr.148.23.723","volume":"148","author":"GC Coles","year":"2001","unstructured":"Coles GC, Stafford KA: Activity of oxyclozanide, nitroxynil, clorsulon and albendazole against adult triclabendazole-resistant Fasciola hepatica. Vet Rec. 2001, 148: 723-724.","journal-title":"Vet Rec"},{"key":"188_CR23","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.vetpar.2009.02.004","volume":"162","author":"M McConville","year":"2009","unstructured":"McConville M, Brennan GP, Flanagan A, Edgar HWJ, Hanna REB, McCoy M, Gordon AW, Castillo R, Hern\u00e1ndez-Campos A, Fairweather I: An evaluation of the efficacy of compound alpha and triclabendazole against two isolates of Fasciola hepatica. Vet Parasitol. 2009, 162: 75-88. 10.1016\/j.vetpar.2009.02.004.","journal-title":"Vet Parasitol"},{"key":"188_CR24","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/bdd.2510130204","volume":"13","author":"C Lanusse","year":"1992","unstructured":"Lanusse C, Prichard R: Methimazole increases the plasma concentration of the albendazole metabolites of netobimin in sheep. Biopharm Drug Dispos. 1992, 13: 95-103. 10.1002\/bdd.2510130204.","journal-title":"Biopharm Drug Dispos"},{"key":"188_CR25","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/0304-4017(95)00806-2","volume":"58","author":"IB Wood","year":"1995","unstructured":"Wood IB, Amaral NK, Bairden K, Duncan JL, Kassai T, Malone JB, Pankavich JA, Reinecke RK, Slocombe O, Taylor SM, Vercruysse J: World Association for the Advancement of Veterinary Parasitology (W.A.A.V.P.) second edition of guidelines for evaluating the efficacy of anthelmintics in ruminants (bovine, ovine, caprine). Vet Parasitol. 1995, 58: 181-213. 10.1016\/0304-4017(95)00806-2.","journal-title":"Vet Parasitol"},{"key":"188_CR26","doi-asserted-by":"crossref","DOI":"10.1201\/b14095","volume-title":"Pharmacokinetics","author":"M Gibaldi","year":"1982","unstructured":"Gibaldi M, Perrier D: Pharmacokinetics. New York, Marcel Dekker 1982."},{"key":"188_CR27","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/j.1365-2885.1987.tb00078.x","volume":"10","author":"D Hennessy","year":"1987","unstructured":"Hennessy D, Lacey E, Steel J, Prichard R: The kinetics of triclabendazole disposition in sheep. J Vet Pharmacol Therap. 1987, 10: 64-72. 10.1111\/j.1365-2885.1987.tb00078.x.","journal-title":"J Vet Pharmacol Therap"},{"key":"188_CR28","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/j.1365-2885.1995.tb00578.x","volume":"18","author":"C Lanusse","year":"1995","unstructured":"Lanusse C, Gascon L, Prichard R: Comparative plasma disposition kinetics of albendazole, fenbendazole, oxfendazole and their metabolites in adult sheep. J Vet Pharmacol Therap. 1995, 18: 196-203. 10.1111\/j.1365-2885.1995.tb00578.x.","journal-title":"J Vet Pharmacol Therap"},{"key":"188_CR29","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/0034-5288(95)90106-X","volume":"58","author":"C Lanusse","year":"1995","unstructured":"Lanusse C, Gascon L, Prichard R: Influence of the antithyroid compound methimazole on the plasma disposition of fenbendazole and oxfendazole in sheep. Res Vet Sci. 1995, 58: 222-226. 10.1016\/0034-5288(95)90106-X.","journal-title":"Res Vet Sci"},{"key":"188_CR30","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/0034-5288(91)90082-Y","volume":"51","author":"C Lanusse","year":"1991","unstructured":"Lanusse C, Prichard R: Enhancement of the plasma concentration of albendazole sulphoxide in sheep following coadministration of parenteral netobimin and liver oxidase inhibitors. Res Vet Sci. 1991, 51: 306-312.","journal-title":"Res Vet Sci"},{"key":"188_CR31","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/BF00316107","volume":"39","author":"U Klotz","year":"1990","unstructured":"Klotz U, Ogbuokiri J, Okonkwo P: Ivermectin binds avidly to plasma proteins. Eur J Clin Pharmacol. 1990, 39: 607-608. 10.1007\/BF00316107.","journal-title":"Eur J Clin Pharmacol"},{"issue":"Suppl A","key":"188_CR32","first-page":"33","volume":"78","author":"MA McCoy","year":"2005","unstructured":"McCoy MA, Fairweather I, Brennan GP, Kenny JM, Ellison S, Forbes AB: The efficacy of nitroxynil and triclabendazole administered synchronously against juvenile triclabendazole-resistant Fasciola hepatica in sheep. Res Vet Sci. 2005, 78 (Suppl A): 33.","journal-title":"Res Vet Sci"}],"container-title":["BMC Veterinary Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1746-6148-6-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T11:57:48Z","timestamp":1630497468000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcvetres.biomedcentral.com\/articles\/10.1186\/1746-6148-6-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2,3]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["188"],"URL":"https:\/\/doi.org\/10.1186\/1746-6148-6-8","relation":{},"ISSN":["1746-6148"],"issn-type":[{"value":"1746-6148","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,2,3]]},"assertion":[{"value":"27 August 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2010","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2010","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"8"}}